←
Phil Molyneaux614 posts
Phil Molyneaux avatar

Phil Molyneaux

@drphilmol

@imperialNHLI Prof of Interstitial lung disease | @asthmalunguk Prof of Respiratory Research | Director NIHR CRF @RBandH and #IPF doctor. Working to #cureIPF

◷ Joined October 2010▧ 36 Photos and videos
Phil Molyneaux avatar
Phil Molyneaux@drphilmol·Jan 30

Join the European Respiratory Society (ERS) this March for the Academy of interstitial lung diseases! This ERS course will provide updates on diagnostic procedures, specific diseases and treatment! Learn more and register: ersnet.org/events/academy-of…

Post attachment
JAMA avatar
⟳ Phil Molyneaux retweeted
JAMA@JAMA_current·Jan 22

📊 Research Summary: Higher doses of nalbuphine ER led to greater cough reduction in idiopathic pulmonary fibrosis; adverse events were consistent with those expected for opioid-class medications. ja.ma/3ZbF1OZ

Post attachment
Trevi Therapeutics avatar
⟳ Phil Molyneaux retweeted
Trevi Therapeutics@TreviThera·Jan 22

Trevi is pleased to announce the publication of data from the Phase 2b IPF chronic cough trial of nalbuphine ER in the Journal of the American Medical Association (JAMA). Read the press release and access the publication here: ow.ly/BORg50Y1jS3 @drphilmol @JAMA_current

0:30
James D Chalmers avatar
⟳ Phil Molyneaux retweeted
James D Chalmers@ProfJDChalmers·Jan 16

Nice to see a joint call for papers from @LancetRespirMed and @ThoraxBMJ for the @BTSrespiratory winter meeting Deadline 30th June. Come on brilliant bronchiectasis and airways colleagues- lets get some great papers in the queue for this 😀 thelancet.com/journals/lanre…

Aran Singanayagam avatar
⟳ Phil Molyneaux retweeted
Aran Singanayagam@SinganayagamLab·Jan 8

We have a one year clinical fellow post (maternity cover) available. Study looking at human viral challenge in bronchiectasis. Would suit IMT or specialist respiratory trainee. Details: imperial.ac.uk/jobs/search-j… Grateful for retweets. Please DM/email if interested.

CHORUS Trial avatar
⟳ Phil Molyneaux retweeted
CHORUS Trial@ChorusTrial·Jan 6

Congratulations to @RBandH for recruiting two participants to the CHORUS Trial in December 🥳

ERS avatar
⟳ Phil Molyneaux retweeted
ERS@EuroRespSoc·22 Sep 2025

If you missed our onsite event in March, why not register for the virtual academy of interstitial lung diseases? This course will cover ILD diagnosis, plus current, novel and future therapies and more! Register now: bit.ly/4izseNx

Post attachment
The BMJ avatar
⟳ Phil Molyneaux retweeted
The BMJ@bmj_latest·28 Oct 2025

The weekly cancer MDT meeting can cause treatment delays, result in poor quality decisions, and waste clinicians’ time, say @tomroques and colleagues. It’s time for a fresh approach bmj.com/content/391/bmj.r224…

NEJM avatar
⟳ Phil Molyneaux retweeted
NEJM@NEJM·27 Aug 2025

In the IMPALA-2 phase 3 trial, the inhaled recombinant human GM-CSF molgramostim improved pulmonary gas transfer in patients with autoimmune pulmonary alveolar proteinosis. Full trial results and Research Summary: nej.md/476PdNU

Post attachment
Laura Fabbri avatar
⟳ Phil Molyneaux retweeted
Laura Fabbri@Istamina·26 Aug 2025

📢 Save the date!
Join us on 10 Sept 2025 for an #ILDIN webinar with @drphilmol 
“From Calm to Crisis: ILD Acute Exacerbations” ➡️ For ILD-IN members. Registration info coming soon via email. #ILD #ERS #LungHealth

ILD-IN@ild_inn25 Aug 2025

It is a great privilege to have @drphilmol as guest speaker for the first in our exciting webinar series on 10th September. Access details have been emailed to ILD-IN members. Don't miss this fantastic opportunity to hear Prof Molyneaux share his expertise in ILD.

Post attachment